Together find the analgesic of tomorrow

The existing pain treatments in gastroenterology are moderately potent and, as is the case for most of them, prone to induce side effects.
Pharma research in this field is very active to develop a better analgesic.

As a close Pharma and Biotech partner, ANS Biotech offers you a unique expertise in this area

Gastroenterology is the branch of medicine which deals with disorders of the stomach and intestines.

A number of related conditions are painful with visceral pain reported as acute, recurrent, or chronic as, for example, in urinary colic, dysmenorrhoea and irritable bowel syndrome (IBS).

Acute or recurrent visceral pain is currently managed quite effectively with fairly low cost analgesics and consequently these conditions do not constitute significant market potential.

IBS, on the other hand, a common chronic bowel disease estimated to affect 15-25% of the worldwide population, with a greater prevalence in women, and accounts for 40-50% of all gastroenterology consultations. IBS is episodic in nature and is characterized by abdominal pain or discomfort and altered bowel habits in the absence of detectable organic disease. IBS has a large impact on QOL with consequent high direct and indirect healthcare costs.

The management of visceral pain is frequently viewed as unsatisfactory because it is typically treated by a range of specialists who take quite different approaches.

How we can help you

Prior to moving into the clinic, preclinical investigations are necessary to evidence the efficacy of your compound in the visceral pain area.
Within a preclinical pain project, four steps may be of value:

1- In terms of compound profiling, we can document the basics for your lead (dose range, side effects, plasma level, CNS exposure).

2- Using a screening approach, we can guide you in the selection of your candidate.

3- We can leverage a broad panel of disease models mimicking the pathophysiology mechanisms of visceral pain to characterize the efficacy of your candidate.

4- We can mitigate the risk associated with clinical development by comparing your candidate versus standard of care agents.

X